Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3623-3629

  Bailey, Howard H ^a   Alberti, Dona B ^a   Thomas, James P ^a   Mulkerin, Daniel L ^a   Binger, Kimberly A ^a   Gottardis, Marco M ^b   Martell, Robert E ^b   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; CARBOPLATIN; CISPLATIN; HORMONE; LOPERAMIDE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG INFUSION; DRUG INHIBITION; ENZYME ACTIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; LEIOMYOSARCOMA; MALE; MAXIMUM TOLERATED DOSE; MONONUCLEAR CELL; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; QT PROLONGATION; SEPSIS; SIDE EFFECT; SOLID TUMOR; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIAZEPINES; FEMALE; HUMANS; IMIDAZOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL;

EID: 34250755529     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0158     Document Type: Article

References (18)

1. Hunt JT, Ding CZ, Batorsky R, et al. The discovery of (R)-7-cyano-2, 3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)- 1H-1, 4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent pre-clinical antitumor activity. J Med Chem2000;43:3587-95.
2. Rose WC, Lee FYF, Fairchild CR, et al. Preclinical antitumor activity of BMS-214662, a highly apoptocic and novel farnesyltransferase inhibitor. Cancer Res 2001;61:7507-17.
3. Ryan DP, Eder JPJ, Puchlaski T, et al. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 2004;10:2222-30.
4. Tabernero J, Sonnichsen D, Albanell J, et al. A phase I pharmacokinetic (PK) and serial tumor and PMBC pharmacodynamic (PD) study of weekly BMS-214662, a farnesyltransferase (FT) inhibitor, in patients with advanced solid tumors [abstract 304]. Proc Am Soc Clin Oncol 2001;20:774.
5. Liu M, Bryant MS, Chen J, et al. Antitumor activity of SCH-66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998;58:4947-56.
6. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming ST1571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002;100:1068-71.
7. Ellis CA, Vos MD, Wickline M, et al. Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat 2003;78:59-67.
8. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones. Proc Natl Acad Sci U S A 1998;95:1369-74.
9. Suzuki N, Del Villar K, Tamanoi F. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc Natl Acad Sci U S A 1998;95:10499-504.
10. Lee FY, Arico M, Camuso A, et al. The FT inhibitor BMS-214662 selectively targets the non-proliferating cell subpopulation in solid tumors - Implications for a synergistic therapeutic strategy [abstract 260s]. Proc Am Assoc Cancer Res 2001;42:260.
11. Lee FYF, Arico M, Camuso A, et al. The pro-apoptotic FT inhibitor BMS-214662 produced synergistic antitumor activity in combination chemotherapy with antiproliferative cytotoxic agents [abstract 3734S]. Clin Cancer Res 2001;7:3734.
12. Mackay HJ, Hoekstra R, Eskens FA, et al. A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res 2004;10:2636-44.
13. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
14. Dy GK, Bruzek LM, Croghan GA, et al. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin Cancer Res 2005;11:1877-83.
15. Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994;27:256-69.
16. Cortes J, Faderl S, Estey E, et al. Phase I study of BMS-214662, a farnesyltransferase inhibitor in patients with acute leukemias and high-risk myelodys-plastic syndromes. J Clin Oncol 2005;23:2805-12.
17. Papadimitrakopoulou V, Agelaki S, Tran HT, et al. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. Clin Cancer Res 2005;11:4151-9.
18. Tabanero J, Rojo F, Marimon I, et al. Phase I pharmacokinetic pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2005;23:2521-33.